U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07465835) titled 'A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)' on March 04.
Brief Summary: This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants >=18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Study Start Date: Feb. 17
Study Type: INTERVENTIONAL
Condition:
T Cell Malignancies
Intervention:
DRUG: ELA026
Weekly maintenance dosing via subcutaneous injection
Recruitment Status: RECRUITING
Sponsor: Electra Therapeutics Inc.
Published by HT Digital Content Services with permission from He...